Gene Editing Therapeutics Market, By Technology (CRISPR, ZFN, TALEN, Base Editing, and RNA Editing), By Development Stage, By Therapy Type, By Disease Indication, By End User, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
REPORT HIGHLIGHT
Gene Editing Therapeutics Market size was valued at US$ 11.13 Million in 2024, expanding at a CAGR of 147.20% from 2025 to 2032.
The Gene Editing Therapeutics Market focuses on the development and commercialization of treatments that modify or correct genetic mutations at the DNA level to treat or potentially cure diseases. With the growing number of approvals for gene-editing therapies targeting rare and inherited disorders, the market is rapidly expanding into areas such as oncology and infectious diseases. A landmark achievement occurred in 2023 when the U.S. FDA approved the first CRISPR-based therapy for sickle cell anemia, signaling a major advancement in clinical gene editing. Innovations like base editing and prime editing are improving the precision of gene-editing technologies while reducing off-target effects, thereby enhancing safety for therapeutic applications. Despite these advancements, challenges remain, including high treatment costs, ethical concerns, and complex regulatory requirements, which limit widespread adoption. Nevertheless, significant opportunities exist in personalized medicine, targeting previously untreatable conditions, and expanding gene-editing applications to more common diseases. This growth is supported by increased research funding from national health agencies and global collaborations within the biotech industry.
Gene Editing Therapeutics Market- Market Dynamics
Breakthrough Clinical Approvals and Precision Tools to Boost Therapeutic Adoption
Breakthrough clinical approvals and precision tools are driving significant growth in the adoption of gene editing therapeutics worldwide. The U.S. FDA’s landmark 2023 approval of the first CRISPR-based therapy for sickle cell disease, developed through a partnership between Vertex Pharmaceuticals and CRISPR Therapeutics, marked a pivotal moment in the clinical application of gene editing. Concurrently, the National Institutes of Health (NIH) has increased funding for precision genome engineering research, advancing technologies such as base editing and prime editing that offer greater accuracy with fewer off-target effects. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) has introduced accelerated review pathways for gene-editing therapies to expedite access to cutting-edge treatments. These initiatives underscore a growing global focus on the safe, efficient, and scalable use of gene editing, highlighting its transformative potential in treating inherited disorders, cancers, and complex diseases.
Gene Editing Therapeutics Market- Segmentation Analysis:
The Global Gene Editing Therapeutics Market is segmented on the basis of Technology, Development Stage, Therapy Type, Disease Indication, End User, and Region.
The gene editing market is segmented by technology into five key categories: CRISPR, Zinc Finger Nucleases (ZFN), Transcription Activator-Like Effector Nucleases (TALEN), Base Editing, and RNA Editing. CRISPR leads the market owing to its simplicity, high efficiency, and broad applicability across various genetic modifications. ZFN offers high specificity but involves more complex design processes, making it suitable for targeted therapeutic applications. TALEN technology is highly valued for its precision in gene knockout studies, providing a reliable tool for functional genomics. Base editing allows for precise single-nucleotide changes without causing double-stranded DNA breaks, enabling safer and more controlled gene edits. RNA editing facilitates transient and reversible modifications at the RNA level without altering the underlying DNA sequence, offering therapeutic potential with reduced risk of permanent off-target effects. According to the U.S. National Institutes of Health (NIH), funding for gene editing technologies, particularly CRISPR, has increased by over 25% in the last five years, reflecting government support to accelerate research and clinical applications.
Based on development stages, the gene editing market is divided into Preclinical, Phase I, Phase II, Phase III, and Approved therapy categories. The Preclinical stage dominates the market with a large number of gene editing candidates undergoing laboratory and animal testing to assess safety and initial efficacy. Phase I clinical trials focus on evaluating safety profiles in a small group of human subjects, while Phase II trials explore therapeutic efficacy in a larger patient population. Phase III involves large-scale validation of treatment safety and effectiveness across diverse populations, often determining regulatory approval. Approved therapies represent successful transitions from research to clinical use, particularly gaining traction in treating rare genetic disorders such as sickle cell disease and certain forms of inherited blindness. The U.S. Food and Drug Administration (FDA) reports that gene therapies have seen a steady rise in approvals, with over 20 gene-editing-based therapies authorized since 2017, highlighting the growing impact of these advanced treatments supported by government regulatory frameworks.
Gene Editing Therapeutics Market- Geographical Insights
The Gene Editing Therapeutics Market demonstrates strong regional variations, with North America leading due to its advanced biotechnology infrastructure, robust clinical research activity, and supportive regulatory environment driven by agencies like the FDA. The U.S. dominates in CRISPR-based therapy approvals and clinical trials, supported by significant public and private investments— the NIH alone allocated over $2 billion to gene therapy research in 2023. Europe follows closely, with countries such as the UK, Germany, and Switzerland actively investing in precision medicine, while regulatory bodies like the EMA show increasing openness to innovative genetic treatments.
The Asia-Pacific region is rapidly emerging, particularly in China and Japan, where government initiatives and biotech collaborations are accelerating gene editing research. China’s proactive role in clinical trials and regulatory reforms is fostering a competitive market landscape, supported by its National Natural Science Foundation allocating approximately $500 million to gene-editing projects in 2023. Meanwhile, Latin America and the Middle East & Africa are gradually entering the field through academic partnerships and pilot programs, focusing on building capacity and adapting regulatory frameworks to support future integration of gene therapies. This global government funding and regulatory support collectively drive the expansion and innovation of gene editing therapeutics worldwide.
Gene Editing Therapeutics Market- Competitive Landscape:
The competitive landscape of the Gene Editing Therapeutics Market is defined by a diverse mix of biotechnology firms, pharmaceutical companies, and academic research institutions dedicated to advancing safe and effective gene-editing treatments. Leading players are actively developing therapies based on CRISPR, TALEN, and zinc finger nuclease (ZFN) technologies, targeting a broad spectrum of genetic and chronic diseases. Collaborations between innovative biotech startups and established pharmaceutical companies have become increasingly prevalent, accelerating clinical development and regulatory approvals. Significant progress includes partnerships focused on co-developing CRISPR-based therapies for blood disorders and CAR-T cell engineering for cancer treatment. Academic institutions play a critical role in early-stage research and refinement of gene-editing tools, which are often licensed to commercial entities for therapeutic application. Key strategic initiatives—such as exclusive licensing agreements, expansion into global markets, and investment in GMP-compliant manufacturing facilities—are essential for gaining competitive advantage, with a strong emphasis on developing personalized and potentially curative therapies.
Recent Developments:
- In May 2025, CRISPR Therapeutics and Sirius Therapeutics announced a multi-target collaboration to develop novel siRNA therapies, including SRSD107 for thromboembolic disorders, aiming to deliver best-in-class, long-acting gene-based treatments with infrequent dosing and improved patient outcomes.
- In May 2025, NIH-supported researchers administered the first personalized CRISPR gene-editing therapy to an infant with CPS1 deficiency. Utilizing a rapid, customizable platform, the treatment successfully corrected the genetic defect in liver cells within six months, marking a breakthrough in rare disease therapeutics.
- In November 2023, Vertex Pharmaceuticals and CRISPR Therapeutics received regulatory approval for the world’s first CRISPR-based gene editing therapy targeting sickle cell disease and beta thalassemia, a historic milestone offering new hope to patients with these genetic disorders.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL GENE EDITING THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- ArsenalBio
- Beam Therapeutics
- Caribou Biosciences
- CRISPR Therapeutics
- Editas Medicine
- EditForce
- Excision BioTherapeutics
- Graphite Bio
- Homology Medicines
- Intellia Therapeutics
- LogicBio Therapeutics
- Poseida Therapeutics
- Precision BioSciences
- Recombinetics
- Sangamo Therapeutics
- Verve Therapeutics
- Others
GLOBAL GENE EDITING THERAPEUTICS MARKET, BY TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032
- CRISPR
- ZFN
- TALEN
- Base Editing
- RNA Editing
GLOBAL GENE EDITING THERAPEUTICS MARKET, BY DEVELOPMENT STAGE- MARKET ANALYSIS, 2019 - 2032
- Preclinical
- Phase I
- Phase II
- Phase III
- Approved
GLOBAL GENE EDITING THERAPEUTICS MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032
- In Vivo Gene Editing
- Ex Vivo Gene Editing
GLOBAL GENE EDITING THERAPEUTICS MARKET, BY DISEASE INDICATION- MARKET ANALYSIS, 2019 - 2032
- Hematologic Disorders
- Genetic Disorders (e.g., Sickle Cell, DMD)
- Cancer
- Infectious Diseases
- Eye Disorders
GLOBAL GENE EDITING THERAPEUTICS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032
- Hospitals
- Specialty Clinics
- Research Organizations
- Biopharma Companies
GLOBAL GENE EDITING THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Gene Editing Therapeutics Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Gene Editing Therapeutics Market Snippet by Technology
2.1.2. Gene Editing Therapeutics Market Snippet by Development Stage
2.1.3. Gene Editing Therapeutics Market Snippet by Therapy Type
2.1.4. Gene Editing Therapeutics Market Snippet by Disease Indication
2.1.5. Gene Editing Therapeutics Market Snippet by End User
2.1.6. Gene Editing Therapeutics Market Snippet by Country
2.1.7. Gene Editing Therapeutics Market Snippet by Region
2.2. Competitive Insights
3. Gene Editing Therapeutics Key Market Trends
3.1. Gene Editing Therapeutics Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Gene Editing Therapeutics Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Gene Editing Therapeutics Market Opportunities
3.4. Gene Editing Therapeutics Market Future Trends
4. Gene Editing Therapeutics Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Gene Editing Therapeutics Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Gene Editing Therapeutics Market Landscape
6.1. Gene Editing Therapeutics Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Gene Editing Therapeutics Market – By Technology
7.1. Overview
7.1.1. Segment Share Analysis, By Technology, 2024 & 2032 (%)
7.1.2. CRISPR
7.1.3. ZFN
7.1.4. TALEN
7.1.5. Base Editing
7.1.6. RNA Editing
8. Gene Editing Therapeutics Market – By Development Stage
8.1. Overview
8.1.1. Segment Share Analysis, By Development Stage, 2024 & 2032 (%)
8.1.2. Preclinical
8.1.3. Phase I
8.1.4. Phase II
8.1.5. Phase III
8.1.6. Approved
9. Gene Editing Therapeutics Market – By Therapy Type
9.1. Overview
9.1.1. Segment Share Analysis, By Therapy Type, 2024 & 2032 (%)
9.1.2. In Vivo Gene Editing
9.1.3. Ex Vivo Gene Editing
10. Gene Editing Therapeutics Market – By Disease Indication
10.1. Overview
10.1.1. Segment Share Analysis, By Disease Indication, 2024 & 2032 (%)
10.1.2. Hematologic Disorders
10.1.3. Genetic Disorders (e.g., Sickle Cell, DMD)
10.1.4. Cancer
10.1.5. Infectious Diseases
10.1.6. Eye Disorders
11. Gene Editing Therapeutics Market – By End User
11.1. Overview
11.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
11.1.2. Hospitals
11.1.3. Specialty Clinics
11.1.4. Research Organizations
11.1.5. Biopharma Companies
12. Gene Editing Therapeutics Market– By Geography
12.1. Introduction
12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
12.2. North America
12.2.1. Overview
12.2.2. Gene Editing Therapeutics Key Manufacturers in North America
12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.2.4. North America Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.2.5. North America Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.2.6. North America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.2.7. North America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.2.9. U.S.
12.2.9.1. Overview
12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.2.9.3. U.S. Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.2.9.4. U.S. Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.2.9.5. U.S. Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.2.9.6. U.S. Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.2.9.7. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.2.10. Canada
12.2.10.1. Overview
12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.2.10.3. Canada Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.2.10.4. Canada Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.2.10.5. Canada Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.2.10.6. Canada Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.2.10.7. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3. Europe
12.3.1. Overview
12.3.2. Gene Editing Therapeutics Key Manufacturers in Europe
12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.3.4. Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.3.5. Europe Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.3.6. Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.7. Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.9. Germany
12.3.9.1. Overview
12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.9.3. Germany Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.3.9.4. Germany Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.3.9.5. Germany Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.9.6. Germany Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.3.9.7. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.10. UK
12.3.10.1. Overview
12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.10.3. UK Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.3.10.4. UK Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.3.10.5. UK Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.10.6. UK Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.3.10.7. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.11. France
12.3.11.1. Overview
12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.11.3. France Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.3.11.4. France Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.3.11.5. France Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.11.6. France Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.3.11.7. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.12. Italy
12.3.12.1. Overview
12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.12.3. Italy Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.3.12.4. Italy Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.3.12.5. Italy Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.12.6. Italy Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.3.12.7. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.13. Spain
12.3.13.1. Overview
12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.13.3. Spain Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.3.13.4. Spain Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.3.13.5. Spain Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.13.6. Spain Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.3.13.7. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.14. The Netherlands
12.3.14.1. Overview
12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.14.3. The Netherlands Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.3.14.4. The Netherlands Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.3.14.5. The Netherlands Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.14.6. The Netherlands Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.15. Sweden
12.3.15.1. Overview
12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.15.3. Sweden Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.3.15.4. Sweden Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.3.15.5. Sweden Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.15.6. Sweden Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.3.15.7. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.16. Russia
12.3.16.1. Overview
12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.16.3. Russia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.3.16.4. Russia Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.3.16.5. Russia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.16.6. Russia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.3.16.7. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.17. Poland
12.3.17.1. Overview
12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.17.3. Poland Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.3.17.4. Poland Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.3.17.5. Poland Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.17.6. Poland Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.3.17.7. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.18. Rest of Europe
12.3.18.1. Overview
12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.18.3. Rest of the Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.3.18.4. Rest of the Europe Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.3.18.5. Rest of the Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.3.18.6. Rest of the Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4. Asia Pacific (APAC)
12.4.1. Overview
12.4.2. Gene Editing Therapeutics Key Manufacturers in Asia Pacific
12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.4.4. APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.4.5. APAC Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.4.6. APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.7. APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.4.8. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.9. China
12.4.9.1. Overview
12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.9.3. China Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.4.9.4. China Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.4.9.5. China Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.9.6. China Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.4.9.7. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.10. India
12.4.10.1. Overview
12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.10.3. India Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.4.10.4. India Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.4.10.5. India Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.10.6. India Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.4.10.7. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.11. Japan
12.4.11.1. Overview
12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.11.3. Japan Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.4.11.4. Japan Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.4.11.5. Japan Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.11.6. Japan Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.4.11.7. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.12. South Korea
12.4.12.1. Overview
12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.12.3. South Korea Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.4.12.4. South Korea Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.4.12.5. South Korea Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.12.6. South Korea Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.4.12.7. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.13. Australia
12.4.13.1. Overview
12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.13.3. Australia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.4.13.4. Australia Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.4.13.5. Australia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.13.6. Australia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.4.13.7. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.14. Indonesia
12.4.14.1. Overview
12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.14.3. Indonesia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.4.14.4. Indonesia Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.4.14.5. Indonesia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.14.6. Indonesia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.4.14.7. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.15. Thailand
12.4.15.1. Overview
12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.15.3. Thailand Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.4.15.4. Thailand Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.4.15.5. Thailand Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.15.6. Thailand Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.4.15.7. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.16. Philippines
12.4.16.1. Overview
12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.16.3. Philippines Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.4.16.4. Philippines Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.4.16.5. Philippines Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.16.6. Philippines Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.4.16.7. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.17. Rest of APAC
12.4.17.1. Overview
12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.17.3. Rest of APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.4.17.4. Rest of APAC Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.4.17.5. Rest of APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.4.17.6. Rest of APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5. Latin America (LATAM)
12.5.1. Overview
12.5.2. Gene Editing Therapeutics Key Manufacturers in Latin America
12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.5.4. LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.5.5. LATAM Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.5.6. LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.5.7. LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.5.8. LATAM Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.9. Brazil
12.5.9.1. Overview
12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.9.3. Brazil Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.5.9.4. Brazil Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.5.9.5. Brazil Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.5.9.6. Brazil Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.5.9.7. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.10. Mexico
12.5.10.1. Overview
12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.10.3. Mexico Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.5.10.4. Mexico Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.5.10.5. Mexico Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.5.10.6. Mexico Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.5.10.7. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.11. Argentina
12.5.11.1. Overview
12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.11.3. Argentina Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.5.11.4. Argentina Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.5.11.5. Argentina Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.5.11.6. Argentina Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.5.11.7. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.12. Colombia
12.5.12.1. Overview
12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.12.3. Colombia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.5.12.4. Colombia Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.5.12.5. Colombia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.5.12.6. Colombia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.5.12.7. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.13. Rest of LATAM
12.5.13.1. Overview
12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.13.3. Rest of LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.5.13.4. Rest of LATAM Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.5.13.5. Rest of LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.5.13.6. Rest of LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6. Middle East and Africa
12.6.1. Overview
12.6.2. Gene Editing Therapeutics Key Manufacturers in Middle East and Africa
12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.6.4. Middle East and Africa Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.6.5. Middle East and Africa Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.6.6. Middle East and Africa Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.6.7. Middle East and Africa Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.9. Saudi Arabia
12.6.9.1. Overview
12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.9.3. Saudi Arabia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.6.9.4. Saudi Arabia Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.6.9.5. Saudi Arabia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.6.9.6. Saudi Arabia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.10. United Arab Emirates
12.6.10.1. Overview
12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.10.3. United Arab Emirates Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.6.10.4. United Arab Emirates Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.6.10.5. United Arab Emirates Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.6.10.6. United Arab Emirates Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.11. Israel
12.6.11.1. Overview
12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.11.3. Israel Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.6.11.4. Israel Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.6.11.5. Israel Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.6.11.6. Israel Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.6.11.7. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.12. Turkey
12.6.12.1. Overview
12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.12.3. Turkey Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.6.12.4. Turkey Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.6.12.5. Turkey Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.6.12.6. Turkey Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.6.12.7. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.13. Algeria
12.6.13.1. Overview
12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.13.3. Algeria Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.6.13.4. Algeria Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.6.13.5. Algeria Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.6.13.6. Algeria Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.6.13.7. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.14. Egypt
12.6.14.1. Overview
12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.14.3. Egypt Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.6.14.4. Egypt Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.6.14.5. Egypt Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.6.14.6. Egypt Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.6.14.7. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.15. Rest of MEA
12.6.15.1. Overview
12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.15.3. Rest of MEA Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
12.6.15.4. Rest of MEA Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
12.6.15.5. Rest of MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
12.6.15.6. Rest of MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
13. Key Vendor Analysis- Gene Editing Therapeutics Industry
13.1. Competitive Dashboard
13.1.1. Competitive Benchmarking
13.1.2. Competitive Positioning
13.2. Company Profiles
13.2.1. ArsenalBio
13.2.2. Beam Therapeutics
13.2.3. Caribou Biosciences
13.2.4. CRISPR Therapeutics
13.2.5. Editas Medicine
13.2.6. EditForce
13.2.7. Excision BioTherapeutics
13.2.8. Graphite Bio
13.2.9. Homology Medicines
13.2.10. Intellia Therapeutics
13.2.11. LogicBio Therapeutics
13.2.12. Poseida Therapeutics
13.2.13. Precision BioSciences
13.2.14. Recombinetics
13.2.15. Sangamo Therapeutics
13.2.16. Verve Therapeutics
13.2.17. Others
14. 360 Degree Analyst View
15. Appendix
15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us
